Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update LONDON, February 27, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported ...

$SLN to focus cash on #divesiran for #polycythemiavera. Enrolment in p2 to be complete in 2025.

Progression of #zerlasiran for Lpa lowering into p3 (as expected) pending partnership.

Cash runway into 2027.

$PTGX

finance.yahoo.com/news/silence...

Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) This phase 2 randomized clinical trial evaluates the optimal dose, dosing interval, and safety of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), to treat patient...

Zerlasiran, RNA de interferencia dirigido a síntesis hepática de apolipoproteína(a), es bien tolerada y reduce concentración de lipoproteína(a) en más de 80% durante 36 sem de tratamiento en pacientes con enfermedad CV aterosclerótica #ASCVD #zerlasiran #lipoprotein jamanetwork.com/journals/jam...

Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) This phase 2 randomized clinical trial evaluates the optimal dose, dosing interval, and safety of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), to treat patient...

Zerlasiran, RNA pequeño de interferencia dirigido a la síntesis hepática de apolipoproteína(a), reduce la concentración de lipoproteína(a) en más del 80% a las 36sem de tratamiento en pacientes con enfermedad CV aterosclerótica jamanetwork.com/journals/jam... ASCVD #zerlasiran #lipoprotein

#AHA24 Please stay around to this afternoon's late breaking clinical trial session on #lipids! Phase 2 data for 2 new #LPa therapeutics ( #zerlasiran & #muvalaplin)
and phase 3 data of #obicetrapib for LDL-C lowering in HeFH. #CardioSky @ahascience.bsky.social